Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concerns

Dr Reddy's shares fell 7% after the company disclosed that certain batches of semaglutide failed quality specifications due to an API-related issue, delaying commercial supplies until the root cause is identified. The company clarified there is no impact on patient safety or existing global regulatory filings, and management will host a conference call to address the development. The stock weakness comes alongside weak Q4 FY26 results, with consolidated net profit plunging 86% YoY to Rs 221 crore and revenue declining 12% YoY to Rs 7,516 crore.